Optimization of novel compounds using computer‐aided drug design for treatment of cardiac arrhythmia
British Journal of Pharmacology · 2026-09 · 183 (17) · 5407-5420
DOI: 10.1111/bph.70532 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 15.06.2026. Verfasst von Jessica Jowais und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biophysics, Miller School of Medicine, University of Miami, Miami, Florida, USA. Hauptthemen laut MEDLINE: Drug Design, KCNQ1 Potassium Channel, Computer-Aided Design, Arrhythmias, Cardiac. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, CIHR, Canada Research Chairs.
Abstract (Originalsprache)
Background and Purpose Loss‐of‐function mutations of the voltage‐gated K v 7.1 (KCNQ/KCNE1) channels lead to cardiac arrhythmia such as long QT syndrome, characterized by a prolonged QT interval . One strategy to correct the prolonged QT interval is to design molecules that activate KCNQ1/KCNE1 channels and restore the QT interval. However, there are currently no clinically approved KCNQ1/KCNE1 activators. Polyunsaturated fatty acids (PUFAs) have been shown to be potent activators of KCNQ1/KCNE1, increasing KCNQ1/KCNE1 currents and shortening the action potential duration in human cardiomyocytes. However, PUFAs are unspecific and have many targets, including other cardiac ion channels. Experimental Approach In this study, Site Identification by Ligand Competitive Saturation was used in combination with electrophysiology to optimize compounds that bind to the PUFA binding sites, increasing both their potency and site specificity. Key Results Two compounds, Compound 1‐ linoleic acid (LIN) and Compound 2‐LIN, exhibited a more potent activation effect on KCNQ1/KCNE1 channels than our previous PUFA analogues, with each compound demonstrating a distinct activation mechanism. Conclusion and Implications These findings highlight the potential of computer‐aided drug design in developing more targeted and effective KCNQ1/KCNE1 activators, paving the way for personalized therapeutic strategies in treating cardiac disorders. Although the small molecule screening identified compounds with favourable interactions at PUFA binding sites, a lipid tail was required for their effect. This strategy of incorporating lipid tails onto small molecules offers a novel approach for targeting the underexplored transmembrane regions of membrane proteins, which could significantly impact drug development for a wide range of therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Biophysics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
- Centre for Molecular Simulation and Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada.
- Department of Biomedical and Clinical Sciences (BKV), Linköping University, Linköping, Sweden.
Förderung
- NHLBI NIH HHS
- CIHR
- Canada Research Chairs
- Digital Research Alliance of Canada
- NIH HHS
- Swedish Research Council
- Vetenskapsrådet
- Canadian Institutes of Health Research
Zitieren
APA
Jowais, J., Castro-Gonzalez, L. M., Golluscio, A., Tieleman, D. P., & Larsson, H. P. (2026). Optimization of novel compounds using computer‐aided drug design for treatment of cardiac arrhythmia. British Journal of Pharmacology, 183(17), 5407-5420. https://doi.org/10.1111/bph.70532
Vancouver
Jowais J, Castro-Gonzalez LM, Golluscio A, Tieleman DP, Larsson HP. Optimization of novel compounds using computer‐aided drug design for treatment of cardiac arrhythmia. British Journal of Pharmacology. 2026;183(17):5407-5420. doi:10.1111/bph.70532
BibTeX
@article{Jowais2026,
author = {Jowais, Jessica and Castro-Gonzalez, Laura M and Golluscio, Alessia and Tieleman, D Peter and Larsson, H Peter},
title = {Optimization of novel compounds using computer‐aided drug design for treatment of cardiac arrhythmia},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {17},
pages = {5407--5420},
doi = {10.1111/bph.70532}
}
EUVIMED